Arm A (Mel-Dex) [clinicaltrials_resource:NCT01078454/group/O1]
Patients receive melphalan 0.22 mg/kg orally (PO) and dexamethasone 40 mg PO on days 1-4 every 4 weeks. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
Arm A (Mel-Dex) [clinicaltrials_resource:NCT01078454/group/O1]
Patients receive melphalan 0.22 mg/kg orally (PO) and dexamethasone 40 mg PO on days 1-4 every 4 weeks. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
Bio2RDF identifier
NCT01078454/group/O1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT01078454/group/O1
group id [clinicaltrials_vocabulary:group-id]
description
Patients receive melphalan 0.2 ...... sion or unacceptable toxicity.
@en
identifier
clinicaltrials_resource:NCT01078454/group/O1
title
Arm A (Mel-Dex)
@en
type
label
Arm A (Mel-Dex) [clinicaltrials_resource:NCT01078454/group/O1]
@en